business model is to generate revenue through technology transfer (which
brings in upfront, milestone and royalty payments), product sales,
contract research and production of highly-value added biochemicals. The Company has successfully completed
a number of technology transfers, and begun to manufacture many highly-value
continues to seek alignment with the commercial partners who are the
leaders in her own field for the broader application of its novel enzymes
in food industry, pharmaceutical industry, chemical industry, agriculture
and environmental protection.